Women with BRCA gene mutations face a better prognosis in epithelial ovarian cancer, researchers have found, in a paradoxical twist to the BRCA story.
Despite being at very high risk for ovarian cancer, and more likely to present with higher-grade cancers, new research suggests carriers of BRCA mutations also have substantially better survival.
BRCA2 carriers face the best prognosis, with 52% of patients surviving to five years. BRCA1 carriers have five-year survival rates of 44%, compared to just 36% in non-carriers.
The findings come from a pooled analysis of 26 studies, described in an editorial as "by far the largest study of BRCA-associated ovarian cancer outcomes reported to...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.